首页> 中文期刊> 《中国神经再生研究:英文版》 >NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia

NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia

         

摘要

In the clinic,the natural recovery rate of homonymous hemianopsia caused by occipital lobe infarction is low.At present,ideal therapeutic effects of piracetam for improving visual field defects following homonymous hemianopsia do not exist.The present randomized,controlled study compared the effects of NeuroAid (MLC601) versus piracetam for improving visual field defects in post-infarct homonymous hemianopsia patients matched for age and sex.After 3 months of treatment with NeuroAid (MLC601) or piracetam,visual field defects were significantly improved,compared with prior to treatment (P < 0.001).After treatment with MLC601,relative reduction of right and left visual field defects was 45% and 45.7%,respectively,while relative reduction after treatment with piracetam was 32.7% and 30.3%,respectively.These findings suggested that MLC601 was superior to piracetam for reducing visual field defects in homonymous hemianopsia patients.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号